CRUMP/JCCC Seminar :: Peter Caravan, PhD

Sep 25, 2017 4:00pm to 5:00pm
Moss Auditorium - A2-342 MDCC
Peter Caravan, Ph.D.
Co-Director, Institute for Innovation in Imaging,
Associate Professor, Department of Radiology
Massachusetts General Hospital, Harvard Medical School
"Molecular Imaging of Fibrosis"
Monday, September 25th 2017
4:00 – 5:00 pm
Moss Auditorium - A2-342 MDCC


It is estimated that half of the deaths in the developed world stem from diseases that manifest with a fibroproliferative component. For example atrial fibrillation, myocardial infarction, nonalcoholic steatohepatitis, pulmonary fibrosis, diabetic nephropathy, inflammatory bowel disease, scleroderma, atherosclerosis, muscular dystrophy all involve fibrosis of the heart, liver, lung, kidneys, intestine, skin, blood vessels, and muscles, respectively. Many cancers exhibit a fibrotic phenotype (desmoplastic response). Pro-fibrotic pathways are increasingly the subject of existing and novel therapeutic interventions to treat these diseases. However the available tools for detecting and quantifying fibrosis and for measuring disease change are often absent or inadequate. Biopsy remains the gold standard in many diseases, but biopsy is invasive, suffers sampling error, has complications, and is not suited to repeat studies. Existing imaging techniques are inadequate or limited to advanced disease. None of the existing techniques can distinguish active fibrosis (fibrogenesis) from stable scar. Our lab has been developing PET and MR molecular probes to detect and stage fibrosis and to monitor response to treatment, and have applied these probes to quantify fibrosis in the liver, heart, lung, and in fibrotic tumor stroma. Further, we have developed a novel approach to distinguish active fibrogenesis from stable disease. In this lecture we will describe our efforts in imaging fibrosis and fibrogenesis in a range of animal models of disease and in different organ systems, as well as the translational opportunities provided by these molecular probes.